Trial Profile

A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary) ; Melphalan (Primary) ; Cyclophosphamide; Prednisone
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms EMN02/HOVON 95; HO95

21 Aug 2024 Planned End Date changed from 1 Apr 2024 to 1 Jan 2025.
22 Nov 2023 This study has been completed in Austria, according to European Clinical Trials Database record.
17 Aug 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com